{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.91 vs. cons $2.86",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$25.6B vs. cons $25.3B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Innovative Medicine Segment Sales",
      "prediction": "BEAT",
      "answer": "pred ~$16.35B vs. cons $16.1B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Operational Sales Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$100.6B vs. cons $100.2B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Adjusted Operational EPS Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$11.55 vs. cons $11.42 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Adjusted Pretax Operating Margin Expansion",
      "prediction": "UNCHANGED",
      "answer": "guide ~+55bps vs. cons +50bps (FY2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 0.9,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -0.6,
  "day5_path": "FADE",
  "day5_rationale": "Stock has run +24% YTD to all-time highs pricing in a beat-and-raise, so even a solid Q2 (EPS/sales beat, modest FY raise) likely triggers only a muted pop on day 1. Because Q1's raise was already sizable and margin recovery (Innovative Medicine/MedTech) is only gradually reversing per management's own H1-loaded investment framing, the incremental FY raise this quarter is unlikely to match the magnitude of the quarterly beat - implying H2 buy-side numbers get trimmed at the margin even as headline Q2 prints clean. Combined with a stretched ~22x+ multiple after the rally, this sets up profit-taking/consolidation over the following days (sell-the-news fade) rather than continued follow-through, absent a much larger-than-expected guidance raise or ICOTYDE ramp surprise.",
  "day5_confidence": "LOW"
}